Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer
Clemens Grassberger(University of Washington), Dan G. Duda(Harvard University), Christopher H. Crane(Memorial Sloan Kettering Cancer Center), Thomas F. DeLaney(Massachusetts General Hospital), Eugene J. Koay(The University of Texas MD Anderson Cancer Center), Tai Hato(Harvard University), Theodore S. Hong(Massachusetts General Hospital), Mark Tracy(The University of Sydney), Lipika Goyal(Stanford Medicine), Jennifer Y. Wo(Massachusetts General Hospital), Mark Cobbold(Kala Pharmaceuticals (United States)), Jeffrey W. Clark(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), John A. Wolfgang(Massachusetts General Hospital), Thomas Bortfeld(Harvard University), Beow Y. Yeap(Harvard University), Christine E. Eyler(Duke University)
International Journal of Radiation Oncology*Biology*Physics
April 17, 2018
Cited by 35
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k